Xian Jia

Xian Jia

Auto-generated profile, based on publicly available information

Xian Jia

T-MAXIMUM Pharmaceutical (Suzhou) Co., Ltd., Suzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
QLQiubin Lin
Qiubin Lin
LRLi Rong
Li Rong
XJXian Jia
Xian Jia
RLRenhao Li
Renhao Li
BYBin Yu
Bin Yu
JHJIANDONG HUANG
JIANDONG HUANG
Metastasis accounts for 90% of cancer-related deaths and, currently, there are no effective clinical therapies to block the metastatic cascade. A need to develop novel therapies specifically targeting fundamental metastasis processes remains urgent. Here, we demonstrate that Salmonella YB1, an engineered oxygen-sensitive strain, potently inhibits metastasis of a broad range of cancers. This process requires both IFN-γ and NK cells, as the absence of IFN-γ greatly reduces, whilst depletion of NK cells in vivo completely abolishes, the anti-metastatic ability of Salmonella. Mechanistically, we find that IFN-γ is mainly produced by NK cells during early Salmonella infection, and in turn, IFN-γ promotes the accumulation, activation, and cytotoxicity of NK cells, which kill the metastatic cancer cells thus achieving an anti-metastatic effect. Our findings highlight the significance of a self-regulatory feedback loop of NK cells in inhibiting metastasis, pointing a possible approach to develop anti-metastatic therapies by harnessing the power of NK cells.

28 March 2023 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
JTJian Tang
Jian Tang
XJXian Jia
Xian Jia
JLJian Li
Jian Li
JDJunchen Dong
Junchen Dong
JWJiayu Wang
Jiayu Wang
GFGuo Fu
Guo Fu

6 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXuetao Li
Xuetao Li
XSXiaoyun Shang
Xiaoyun Shang
JLJiangang Liu
Jiangang Liu
YZYang Zhang
Yang Zhang
XJXian Jia
Xian Jia
YHYulun Huang
Yulun Huang
Patients with recurrent high-grade glioblastoma have a median survival of 6-8 months, with limited therapeutic options. In recent years, interest has grown in applying chimeric antigen receptor T (CAR-T) cells to solid cancers, including advanced gliomas. Here we generated off-the-shelf CRISPR-Cas9–edited IL-13Rα2-specific allogeneic universal CAR-T cells (MT026) by disrupting the endogenous TCR to prevent graft-versus-host disease and knocking out HLA class I molecules to mitigate the host-versus-graft response, and observed minimal NK-cell–mediated rejection in preclinical studies. In a first-in-human, single-center, open-label investigator-initiated trial (ChiCTR2000028801) in patients with high-grade glioma with prior therapy failure and short life expectancy, intrathecal injection of MT026 via lumbar puncture (1.0-3.0×10^7 cells per dose) demonstrated favorable tolerability and safety (primary outcome), pharmacokinetic characteristics, and preliminary clinical activity (secondary outcomes). Among the five patients enrolled, one achieved a complete response and three achieved partial responses. No grade ≥3 adverse events were observed; the predominant treatment-related toxicities were grade 1-2 pyrexia, hypoxia, and vomiting. Trial enrolment was halted after enrolment of the first five patients, however these preliminary clinical data support the potential benefit of locally administered allogeneic universal CAR-T cell therapy for recurrent glioblastoma.

8 October 2021 in Science Advances
Verified
Journal Article
Open access
CLChenfeng Liu
Chenfeng Liu
LMLei Ma
Lei Ma
YWYuxuan Wang
Yuxuan Wang
JZJiayi Zhao
Jiayi Zhao
PCPengda Chen
Pengda Chen
WLWen-Hsien Liu
Wen-Hsien Liu
GSK3 controls thymocyte egress by regulating a Foxo1-Klf2-S1P 1 axis through dampening β-catenin–mediated Akt activation.

13 December 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
BHBowen Hou
Bowen Hou
YHYanyan Hu
Yanyan Hu
YZYuzhen Zhu
Yuzhen Zhu
XWXiaocui Wang
Xiaocui Wang
WLWanyun Li
Wanyun Li
GFGuo Fu
Guo Fu
SHP-1 (Src homology region 2 domain-containing phosphatase 1) is a well-known negative regulator of T cells, whereas its close homolog SHP-2 is the long-recognized main signaling mediator of the PD-1 inhibitory pathway. However, recent studies have challenged the requirement of SHP-2 in PD-1 signaling, and follow-up studies further questioned the alternative idea that SHP-1 may replace SHP-2 in its absence. In this study, we systematically investigate the role of SHP-1 alone or jointly with SHP-2 in CD8+ T cells in a series of gene knockout mice. We show that although SHP-1 negatively regulates CD8+ T cell effector function during acute lymphocytic choriomeningitis virus (LCMV) infection, it is dispensable for CD8+ T cell exhaustion during chronic LCMV infection. Moreover, in contrast to the mortality of PD-1 knockout mice upon chronic LCMV infection, mice double deficient for SHP-1 and SHP-2 in CD8+ T cells survived without immunopathology. Importantly, CD8+ T cells lacking both phosphatases still differentiate into exhausted cells and respond to PD-1 blockade. Finally, we found that SHP-1 and SHP-2 suppressed effector CD8+ T cell expansion at the early and late stages, respectively, during chronic LCMV infection.